Mark Frohlich
Company: Indapta Therapeutics
Job title: CEO
Seminars:
Chair’s Opening Remarks 8:25 am
day: Day 2 AM
Panel Discussion: Evaluating Clinical Potential of Different NK Subtypes 11:30 am
Discuss how different NK subtypes perform against various cancer types and disease models How do different NK phenotypes influence therapeutic outcomes? Is it best to have a homogenous or heterogenous NK product?Read more
day: Day 2 - Track B- AM
Panel Discussion: Defining NK Manufacturing Standards for Consistent Product Quality & Synchronized Efforts 8:30 am
Examine key regulatory requirements and compliance issues for NK cell manufacturing, ensuring adherence to industry standards Explore strategies to synchronize manufacturing processes to maintain consistent product quality and performance Discuss key performance indicators and benchmarks for evaluating NK cell manufacturing quality and process improvementsRead more
day: Day 2 AM
Case Study: Key Considerations for Developing a Combination Product 9:30 am
Discussing the development of g-NK cell therapy with antibody combinations for NHL and AML Understanding how to navigate regulations and patient treatment procedures with multiple treatment regiments Highlighting positive clinical data reinforcing the rationale behind a combination approachRead more
day: Day 2 AM
Maximizing NK Expansion for a Robust & Effective Scale-Up of an Allogeneic Product 11:15 am
day: Day 2 - Track B- AM